HedgeChatter

  • Home /
  • Tag Archives

PCRX

4:31 pm Pacira Pharma announced additional Phase 3 data supporting the efficacy and safety of EXPAREL to achieve a femoral nerve block in patients undergoing total knee arthroplasty; sNDA submission expected in Q2 2014

moreView todays social media effects on PCRXView the latest stocks trending across Twitter. Click to view dashboardSee who Pacira is hiring next, click here to view […]

April 4, 2014 Bystocknews , Comments Off on 4:31 pm Pacira Pharma announced additional Phase 3 data supporting the efficacy and safety of EXPAREL to achieve a femoral nerve block in patients undergoing total knee arthroplasty; sNDA submission expected in Q2 2014 read more

EXPAREL Use in Femoral Nerve Block for Total Knee Arthroplasty Further Supported by Additional Data from Phase 3 Pivotal Study, sNDA Submission Planned for Second Quarter 2014

[Business Wire] – Pacira Pharmaceuticals, Inc. today announced additional Phase 3 data supporting the efficacy and safety of EXPAREL® to achieve a femoral nerve block in patients undergoing total knee arthroplasty. moreView todays social media effects on PCRXView the latest stocks trending across Twitter. Click to view dashboardSee who Pacira is hiring next, click here to view […]

April 4, 2014 Bystocknews , Comments Off on EXPAREL Use in Femoral Nerve Block for Total Knee Arthroplasty Further Supported by Additional Data from Phase 3 Pivotal Study, sNDA Submission Planned for Second Quarter 2014 read more

6:30 am Pacira Pharma announces EXPAREL Phase 3 clinical trial in femoral nerve block meets primary efficacy endpoint; sNDA submission expected in second quarter of 2014 with a 10-month PDUFA timeline

moreView todays social media effects on PCRXView the latest stocks trending across Twitter. Click to view dashboardSee who Pacira is hiring next, click here to view […]

February 27, 2014 Bystocknews , Comments Off on 6:30 am Pacira Pharma announces EXPAREL Phase 3 clinical trial in femoral nerve block meets primary efficacy endpoint; sNDA submission expected in second quarter of 2014 with a 10-month PDUFA timeline read more

6:30 am Pacira Pharma announces EXPAREL Phase 3 clinical trial in femoral nerve block meets primary efficacy endpoint; sNDA submission expected in second quarter of 2014 with a 10-month PDUFA timeline

moreView todays social media effects on PCRXView the latest stocks trending across Twitter. Click to view dashboardSee who Pacira is hiring next, click here to view […]

February 27, 2014 Bystocknews , Comments Off on 6:30 am Pacira Pharma announces EXPAREL Phase 3 clinical trial in femoral nerve block meets primary efficacy endpoint; sNDA submission expected in second quarter of 2014 with a 10-month PDUFA timeline read more

Pacira Pharmaceuticals, Inc. Announces EXPAREL Phase 3 Clinical Trial in Femoral Nerve Block Meets Primary Efficacy Endpoint

[at noodls] – sNDA Submission Expected in Second Quarter of 2014 with a 10-month PDUFA Timeline PARSIPPANY, N.J.–(BUSINESS WIRE)–Feb. 27, 2014– Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the … moreView todays social media effects on PCRXView the latest stocks trending across Twitter. Click to view dashboardSee who Pacira is hiring next, click here to view […]

February 27, 2014 Bystocknews , Comments Off on Pacira Pharmaceuticals, Inc. Announces EXPAREL Phase 3 Clinical Trial in Femoral Nerve Block Meets Primary Efficacy Endpoint read more

Pacira pain drug succeeds in late-stage trial

[Reuters] – Pacira Pharmaceuticals Inc said a late-stage trial testing its drug Exparel for a wider use showed the treatment significantly reduced pain compared to placebo in knee surgery patients. Exparel is already approved for use in managing post-sur moreView todays social media effects on PCRXView the latest stocks trending across Twitter. Click to view dashboardSee who Pacira is hiring […]

February 27, 2014 Bystocknews , Comments Off on Pacira pain drug succeeds in late-stage trial read more

Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference

[Business Wire] – Pacira Pharmaceuticals, Inc. today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Barclays Global Healthcare Conference on Thursday, March 13, 2014, a moreView todays social media effects on PCRXView the latest stocks trending across Twitter. Click to view dashboardSee who Pacira is hiring next, click here […]

February 26, 2014 Bystocknews , Comments Off on Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference read more

Wider-than-Expected Loss at Pacira

moreView todays social media effects on PCRXView the latest stocks trending across Twitter. Click to view dashboardSee who Pacira is hiring next, click here to view […]

February 26, 2014 Bystocknews , Comments Off on Wider-than-Expected Loss at Pacira read more

Pacira Pharmaceuticals, Inc. Webcast Replay of 2013 Financial Results Conference Call

[GlobeNewswire] – PARSIPPANY, N.J. — Pacira Pharmaceuticals, Inc. today announced that a replay of the company’s fourth quarter and full-year 2013 financial results conference call, which took place today on Tuesday, February … moreView todays social media effects on PCRXView the latest stocks trending across Twitter. Click to view dashboardSee who Pacira is hiring next, click here to view […]

February 25, 2014 Bystocknews , Comments Off on Pacira Pharmaceuticals, Inc. Webcast Replay of 2013 Financial Results Conference Call read more